PCSK9 and hyperlipidemia: Statins, ezetimibe, and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have been the mainstay treatments to pharmacologically treat hyperlipidemia that nearly always need lifelong treatment, that come along with several potential side effects, putting significant economic and personal burden to the patient and health system overall.